Ionis Pharmaceuticals Inc
(NAS:IONS)
$
35.91
-0.42 (-1.16%)
Market Cap: 5.74 Bil
Enterprise Value: 4.73 Bil
PE Ratio: 0
PB Ratio: 8.65
GF Score: 40/100 Ionis Pharmaceuticals Inc at Citi BioPharma Conference Transcript
Sep 08, 2022 / 12:50PM GMT
Release Date Price:
$44.27
(+1.89%)
David Neil Lebowitz
Citigroup Inc., Research Division - Research Analyst
So good morning, and welcome once again to the Citigroup 17th Annual Biopharma Conference. And I'm happy to have with me this morning from Ionis. If you could introduce yourselves to the crowd and maybe talk about the company's overall mission. It's a platform-based company with a powerful antisense platform.
Questions & Answers
Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Yes, absolutely. Eugene, you want to introduce first?
Eugene Schneider
Ionis Pharmaceuticals, Inc. - Executive VP & Chief Clinical Development Officer
Sure. My name is Eugene Schneider. I had clinical development at Ionis, and I've been there for about 9 years now.
Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO
And I'm Beth Hougen, I'm Ionis' CFO. I've been at the company for 22 years. So I've seen a lot of ups and downs and a lot of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot